Biomarin Pharmaceutical Inc (BMRN)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 188,563 | 149,576 | -75,350 | -48,997 | -94,811 |
| Revenue | US$ in thousands | 2,374,190 | 2,068,670 | 1,832,750 | 1,823,140 | 1,680,280 |
| Pretax margin | 7.94% | 7.23% | -4.11% | -2.69% | -5.64% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $188,563K ÷ $2,374,190K
= 7.94%
Biomarin Pharmaceutical Inc's pretax margin has shown variability in recent years. In the most recent fiscal year ending December 31, 2023, the pretax margin improved to 7.94%, which indicates that the company generated 7.94 cents in pretax profit for every dollar of revenue. This represents an increase from the previous year's pretax margin of 7.23%.
Notably, Biomarin Pharmaceutical Inc experienced negative pretax margins in the fiscal years from 2021 to 2019, with the lowest being -5.64% in 2019. The negative pretax margins during these years suggest that the company incurred pretax losses rather than generating profits.
The improvement in pretax margin in 2023 is a positive sign, indicating that the company may have implemented cost-saving measures, increased operational efficiency, or experienced revenue growth. However, further analysis is needed to understand the factors driving this improvement and to assess the company's overall financial performance and profitability.
Peer comparison
Dec 31, 2023